

Applicants: Michael J. Elliott, et al.

U.S. Serial No.: 08/602,272

Filed: February 16, 1996

Page 2

Accordingly, this application is presently pending, and this Preliminary Amendment and the accompanying CPA papers are being timely filed.

Please amend the subject application as follows:

In the claims:

Please amend claims 6, 8-10, 12-15, 29-32 and 34-37 as follows:

D¹ 6. (Twice Amended) A method of treating or preventing thrombosis in a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the subject.

D² 8. (Twice Amended) The method of claim 6, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

D³ 9. (Thrice Amended) The method of claim 8, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Thrice Amended) The method of claim 8, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

D4
12. (Twice Amended) The method of claim 8, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

D5
13. (Thrice Amended) The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

D6
14. (Twice Amended) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.

15. (Twice Amended) The method of claim 14, wherein the chimeric antibody is monoclonal antibody cA2.

D 7^{only} F27
29. (Twice Amended) A method of decreasing plasma fibrinogen in a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the subject.

30. (Twice Amended) The method of claim 29, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

D8
31. (Thrice Amended) The method of claim 30, wherein the antibody is selected from the group consisting of a humanized antibody